Drug Discoveries FDA Approves Livdelzi (seladelpar) for Primary Biliary Cholangitis TreatmentAugust 15, 20240 Summary FDA grants accelerated approval for Livdelzi (seladelpar) by Gilead Sciences, Inc. for the treatment of primary biliary cholangitis (PBC).…
